Holen Sie sich die Stockscreener-App
1.045
5.98%
0.059
Handel nachbörslich:
1.04
-0.005
-0.48%
Schlusskurs vom Vortag:
$0.986
Offen:
$0.9606
24-Stunden-Volumen:
1.72M
Relative Volume:
0.53
Marktkapitalisierung:
$108.05M
Einnahmen:
$65,300
Nettoeinkommen (Verlust:
$-84.93M
KGV:
-0.6118
EPS:
-1.708
Netto-Cashflow:
$-83.57M
1W Leistung:
-4.13%
1M Leistung:
-9.91%
6M Leistung:
-12.18%
1J Leistung:
-58.86%
1-Tages-Spanne:
$0.9606
$1.06
1-Wochen-Bereich:
$0.95
$1.18
52-Wochen-Spanne:
$0.5632
$2.72
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Firmenname
Inovio Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 410-3134
Adresse
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.045 | 108.05M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-13 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-01-25 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-11-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Fortgesetzt | Jefferies | Hold |
| 2021-09-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Eingeleitet | Jefferies | Hold |
| 2021-03-23 | Eingeleitet | BofA Securities | Neutral |
| 2021-02-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-17 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Hochstufung | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-07-01 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-21 | Eingeleitet | The Benchmark Company | Buy |
| 2020-04-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
| 2017-10-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-06 | Eingeleitet | Citigroup | Buy |
| 2017-06-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Bestätigt | Maxim Group | Buy |
| 2017-03-16 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
Alle ansehen
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Price to sales ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM - TradingView
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals (INO) Short Interest & Short Float | Updated Oct 2026 $INO - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer - Zacks Investment Research
Inovio Pharmaceuticals (INO) Institutional Ownership 2026 $INO - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Updates Bylaws with New Exclusive-Forum Provision - The Globe and Mail
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio advances FDA review: Inovio Pharmaceuticals stock falls 3.77 percent - AD HOC NEWS
Inovio Pharmaceuticals stock fell 4.13 percent before FDA decision - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock approaches its October FDA test - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Debt to equity ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock trades lower as FDA date nears - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as price crosses 200-day moving average - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view - AD HOC NEWS
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com South Africa
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com Nigeria
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - TradingView
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - Yahoo Finance
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com India
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - TradingView
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - Yahoo Finance
INOVIO at Cantor Fitzgerald healthcare conference: FDA decision nears By Investing.com - Investing.com India
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO Steps Up Investor Outreach at New York Conferences - MyChesCo
INO Stockholders Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INOVIO to Participate in Upcoming Investor Conferences - Eastern Progress
Inovio Pharmaceuticals Stock Price Forecast. Should You Buy INO? - StockInvest.us
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as analysts see sharp upside - ad-hoc-news.de
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan
INOVIO to Participate in Upcoming Investor Conferences - PR Newswire
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Finanzdaten der Inovio Pharmaceuticals Inc-Aktie (INO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):